GAL-101 is under clinical development by Galimedix Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect GAL-101’s likelihood of approval (LoA) and phase transition for Glaucoma took place on 03 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GAL-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
GAL-101 is under development for the treatment of glaucoma and dry age-related macular degeneration. The drug candidate is formulated as eye drops and is administered through ophthalmic route. It acts by targeting amyloid beta peptide (amyloid precursor protein).
The drug candidate was also under development for Alzheimers disease and Alzheimer-induced dementia.
Quick View GAL-101 LOA Data
|Highest Development Stage|